Athanor Capital’s Amicus Therapeutics FOLD Stock Holding History

Athanor Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-24,437	Closed	-$241K	–	553
2021 Q1	$241K	Sell	24,437 -46,918	-66%	-$726K	0.01%	644
2020 Q4	$1.65M	Buy	71,355 +25,330	+55%	+$518K	0.04%	222
2020 Q3	$650K	Sell	46,025 -41,441	-47%	-$604K	0.02%	293
2020 Q2	$1.32M	Buy	+87,466	New	+$1.07M	0.07%	154
2020 Q1	–	Sell	-78,800	Closed	-$768K	–	225
2019 Q4	$768K	Buy	78,800 +27,540	+54%	+$252K	0.04%	196
2019 Q3	$411K	Buy	+51,260	New	+$556K	0.03%	170

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Athanor Capital's FOLD Position: Q2 2021 in Review

Athanor Capital sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 24,437 shares — an estimated $241K sold.

Athanor Capital first reported a position in FOLD in Q3 2019 and held it in 6 quarters. The position peaked at $1.65M in Q4 2020. 235 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

Athanor Capital reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
Athanor Capital sold 24,437 Amicus Therapeutics shares in Q2 2021, an estimated $241K.
Athanor Capital first reported a position in Amicus Therapeutics in Q3 2019 and held it in 6 quarters.
Athanor Capital's Amicus Therapeutics position peaked at $1.65M in Q4 2020.
235 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.